Extending Talquetamab Education Beyond the Hospital
Panelists discuss how health care providers must actively educate local oncologists, emergency departments, and community centers about bispecific antibody management as these therapies move from inpatient to outpatient settings, ensuring proper recognition and treatment of adverse effects such as cytokine release syndrome (CRS).
EP: 1.Alan's Multiple Myeloma Journey: Facing a New Diagnosis
EP: 2.Connecting With Multiple Myeloma Support Groups and Online Resources
EP: 3.Alan's Treatment Course and Quality-of-Life Goals
EP: 4.Coordinated Health Care Teams and Caregiver Support
EP: 5.Extending Talquetamab Education Beyond the Hospital
EP: 6.Addressing Early Talquetamab Toxicity Concerns
Health care education initiatives at the University of California, San Francisco have expanded to include local oncologists and community centers as bispecific antibodies transition to outpatient administration. Samantha Shenoy, NP, MSN, and colleagues conduct education sessions for affiliated centers, focusing on managing talquetamab adverse effects, infection prevention, and recognizing treatment-related complications. These educational efforts are crucial as therapies move from academic medical centers to community practice settings.
Emergency department education represents a critical component of comprehensive care coordination, ensuring that emergency physicians can recognize and manage CRS and neurotoxicity when patients present with concerning symptoms. The educational initiatives extend to support groups, where health care providers present information about bispecific antibodies and expected adverse effects to help patients and families prepare for treatment experiences.
The systematic approach to education across multiple health care touchpoints—from community oncology centers to emergency departments to patient support groups—demonstrates the comprehensive planning required for safe bispecific antibody administration. This educational framework ensures that as these therapies become more widely available outside major cancer centers, health care providers throughout the continuum of care are prepared to recognize and manage treatment-related complications appropriately.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
